Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
Kereiakes
D J
DJ
Medical Director, Lindner Center for Research and Education, Cincinnati, OH 45219, USA. lindner@fuse.net
Broderick
T M
TM
Abbottsmith
C
C
Shimshak
T M
TM
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014652:Vascular Diseases / Q000139:chemically induced* / Q000209:etiology
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab